Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with...

Logo PR Newswire
PR Newswire

OSLO, Norway, Nov. 25, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website (www.nordicnanovector.com) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").

The new area includes a recording of the webcast and Question & Answer session, which was held for interested parties, including shareholders, on 24 November. During the webcast, shareholders were provided with a more-detailed presentation of the proposed merger with APIM and were given the opportunity to ask their specific questions regarding the merger plans.

Malene Brondberg, Interim CEO and CFO of Nordic Nanovector, says: "We are happy that so many shareholders attended the webcast we hosted yesterday, where we provided more background on the proposed merger with APIM Therapeutics. After a week of highly productive meetings between the Nordic Nanovector and APIM teams, our confidence in a merged company is even stronger than before. Our largest shareholder Folketrygdfondet confirms that it supports the Board's proposal. We are certain that there is no better alternative, and we encourage all shareholders to vote in favour of the merger proposal."

The proposed merger, which is backed by the Boards of Directors of both companies, is the result of an extensive review conducted by Nordic Nanovector in conjunction with Carnegie Investment Bank ("Carnegie") that explored a range of strategic options for the Company. This review included carefully evaluating a potential stand-alone strategy for Nordic Nanovector, which was deemed not to be a viable option by the Board.

After evaluating 25 possible merger and acquisition opportunities, the Company determined that the merger transaction with APIM represents the best and most exciting opportunity for all of Nordic Nanovector's shareholders given, among other things, the significant and broad potential of ATX-101, a novel anti-cancer peptide currently in Phase 2 trials. In addition, the combined company will have the discovery and development expertise to potentially generate multiple value-enhancing new drug candidates from its technology platforms.

How to register for the general meeting

Shareholders wishing to attend the general meeting must register no later than 29 November 2022 at 16:00 hours (CET). Shareholders can attend in person, by proxy or by casting advance votes. The deadline is the same for proxies and advance votes as personal attendance. Until the deadline, votes already cast may be changed or withdrawn.

Electronic registration of attendance, proxies and advance voting is easily available through the link posted at the Company's website: www.nordicnanovector.com. An individual ref. no. and PIN-code required to access the service have been sent to all shareholders with known address.

Registration of personal attendance and proxies can also be made by mail to Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway, or e-mail to: nis@nordea.com within the deadline. No ref. no. and PIN-code is required for registration by mail or e-mail.

The form of registration of attendance (in person or by proxy) is attached with the notice as made available on Nordic Nanovector's website and on the company's ticker on newsweb.no

Advisers

Carnegie Investment Bank is acting as financial advisor to Nordic Nanovector. Advokatfirmaet Selmer AS is acting as legal advisor to Nordic Nanovector and KPMG AS assisted Nordic Nanovector with financial due diligence and a fairness opinion of the exchange ratio.

Advokatfirmaet Schjødt AS is acting as legal advisor to APIM. The valuation of APIM Therapeutics was conducted by Venture Valuation AG, which has now agreed to be identified.

Contacts

Jan H. Egberts, Chairman of Nordic Nanovector
+31 614672518
janegberts@aol.com

Malene Brondberg, Interim CEO and CFO of Nordic Nanovector
+ 44 7561 431 762
ir@nordicnanovector.com

International Media - Frazer Hall / Mark Swallow (MEDiSTRAVA Consulting)
+44 203 928 6900
nordicnanovector@medistrava.com

Media in NorwayStein Jacob Frisch (Lilleby Frisch)
+47 916 10 911
sjf@lillebyfrisch.no

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company's pipeline includes:

  • Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies incorporating the beta emitter lutetium-177 to treat non-Hodgkin's lymphoma (NHL);
  • Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the alpha-emitting radionuclide lead-212, currently being explored with partner Oranomed for chronic lymphocytic leukaemia;
  • Multiple fully humanized anti-CD37 antibodies with potential in haematological cancers and autoimmune diseases; and
  • A CD37 DOTA CAR-T cell opportunity in haematological cancers, which is being advanced via a research collaboration with the University of Pennsylvania.

Further information can be found at www.nordicnanovector.com.

Important information

This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

Matters discussed in this announcement constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon

various assumptions, many of which are based, in turn, upon further assumptions. Although Nordic Nanovector believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies, and other important factors which are difficult or impossible to predict and are beyond its control.

The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. Nordic Nanovector undertakes no obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities.

Cision View original content:https://www.prnewswire.com/news-releases/nordic-nanovector-launches-dedicated-area-on-its-website-in-norwegian-for-information-on-the-proposed-merger-with-apim-therapeutics-301687205.html

SOURCE Nordic Nanovector

Logo PR Newswire
OSLO, Norway, Nov. 23, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") will host a webcast, including a...

Logo PR Newswire
HealthPress Release2022-11-21 09:32:00
OSLO, Norway, Nov. 21, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") desires to share more information with...

Logo Benzinga
Business / FinanceBy Globe Newswire2022-11-24 19:30:00
COPENHAGEN, Denmark, November 24, 2022 Bavarian Nordic A/S BAVA has today received information about the following transactions of the company's...

Logo Benzinga
Business / FinanceBy Business Wire2022-11-25 12:00:00
Mednow Inc. ( Mednow '' or the Company ) MNOW, Canada's on-demand virtual pharmacy, is pleased to announce the Company will be hosting its quarterly...

Logo PR Newswire
DUBLIN, Nov. 24, 2022 /PRNewswire/ -- The "European New Car Online Marketplaces, 2022" report has been added to ResearchAndMarkets.com's offering. This...

Logo Benzinga
Business / FinanceBy Pr Newswire2022-11-24 14:50:00
Connected Care Leader to Demonstrate Fall Detection and Mobile Safety Innovations HERZLIYA, Israel, Nov. 24, 2022 /PRNewswire/ -- Essence SmartCare, a leader...

Logo EIN Presswire
AutoPress Release2022-11-24 15:15:00
Douglas Insights Major players covered into report are TV SD, Intertek Group plc, Applus+, SGS SA, Bureau Veritas, Eurofins Scientific, MISTRAS Group and...

Logo PR Newswire
TechnologyPress Release2022-11-25 07:14:00
An event of public-private partnership for enhancing digital shifting opportunities of the Cool Japan Strategy of the Japanese Government ~ Demonstrating the...

Logo PR Newswire
RIYADH, Saudi Arabia, Nov. 24, 2022 /PRNewswire/ -- Estonian Business and Innovation Agency, a joint organisation to support entrepreneurship in Estonia and...

Logo EIN Presswire
TechnologyPress Release2022-11-24 21:51:29
Immersive tech leaders at Immerse Global Summit Performance by Sami Tauber, Founder, Director, Chief Metaverse Officer at VNCCII. Immerse Global Summit...

Logo EIN Presswire
TechnologyPress Release2022-11-24 17:00:00
DOVER, DELAWARE, USA, November 24, 2022 / EINPresswire.com / -- In October 2022, the Howly team set a new record number 20,000 user issues were successfully...

Logo PR Newswire
HealthPress Release2022-11-25 07:41:00
GOTHENBURG, Sweden, Nov. 25, 2022 /PRNewswire/ -- Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT study's...

Logo PR Newswire
TechnologyPress Release2022-11-24 14:50:00
Connected Care Leader to Demonstrate Fall Detection and Mobile Safety Innovations HERZLIYA, Israel, Nov. 24, 2022 /PRNewswire/ -- Essence SmartCare, a leader...

Logo PR Newswire
TechnologyPress Release2022-11-25 10:24:00
GURUGRAM, India, Nov. 25, 2022 /PRNewswire/ -- SoftwareONE, a leading global provider of end-to-end software and cloud solutions has partnered with SM Prime...

Logo Benzinga
Business / FinanceBy Pr Newswire2022-11-23 12:35:00
Sapiens IDITSuite will provide a single overview of policies, from issuing proposals, policy documents to payments HOLON, Israel, Nov. 23, 2022 /PRNewswire/...

Logo PR Newswire
TechnologyPress Release2022-11-23 16:00:00
OAKLAND, Calif. and SAN JOSE, Calif., Nov. 23, 2022 /PRNewswire/ -- Cisco is the worldwide leader in technology that powers the Internet. For its IMPACT FY23...

Logo PR Newswire
TechnologyPress Release2022-11-24 23:00:00
BRISBANE, Australia, Nov. 25, 2022 /PRNewswire/ -- On Wednesday this week, Australia's AWS Consulting Partner of the Year (2021) unveiled its latest market...

Logo PR Newswire
TechnologyPress Release2022-11-25 02:45:00
Paiman Allage, CEO of Aries TCO (ariestco.com), and CTO of Advanced IT Labs (advanceditlabs.com), Aries focuses on building enterprise business platforms and...

Logo Benzinga
Business / FinanceBy Pr Newswire2022-11-25 02:45:00
Paiman Allage, CEO of Aries TCO (ariestco.com), and CTO of Advanced IT Labs (advanceditlabs.com), Aries focuses on building enterprise business platforms and...